clinical trial · NCT07197827
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.·phase2·recruiting·n = 424
Advanced Solid TumorYL242YL242; PembrolizumabYL242; 5-FU; LVYL242; Pembrolizumab; 5-FU
brief summary
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
started
Sep 22, 2025
primary completion
Sep 1, 2028
completion
Nov 1, 2028
last updated
Dec 24, 2025
official title
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol